Timing of PSA response to guide cessation of docetaxel in prostate cancer.

被引：0
|
作者：
Dickinson, Peter D.
Malik, Jahangeer
Slevin, Finbar
Sivanandan, Ananth
Clarke, Noel W.
Choudhury, Ananya
Elliott, Tony
机构：
[1] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[2] NHS Lothian, Western Gen Hosp, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16069
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Rechallenge docetaxel versus docetaxel/Bevazizumab at PSA - chemo recurrence after docetaxel therapy in hormone refractary prostate cancer
    Firek, P.
    Thueer, D.
    Pfister, D.
    Brehmer, B.
    Heidenreich, A.
    ONKOLOGIE, 2010, 33 : 97 - 98
  • [22] American Cancer Society's complete guide to prostate cancer.
    Swanton, J
    LIBRARY JOURNAL, 2004, 129 (19) : 79 - 79
  • [23] Prediction of survival benefit from docetaxel chemotherapy with PSA response and PSA half-life in men with metastatic hormone refractory prostate cancer
    North, S. A.
    Hanninen, M.
    Venner, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Early detection of prostate cancer. Is serum PSA testing alone sufficient?
    Boergermann, C.
    vom Dorp, F.
    Breuer, G.
    Kliner, S.
    Ruebben, H.
    UROLOGE, 2010, 49 (11): : 1351 - +
  • [25] Complexed PSA and total gland volume are significant predictors of prostate cancer.
    Levine, R
    Cheli, CD
    Kolker, J
    Roberts, SB
    CLINICAL CHEMISTRY, 2001, 47 (06) : A129 - A129
  • [26] Complexed PSA combined with clinical parameters enhances prediction of prostate cancer.
    Cheli, CD
    Thiel, RP
    Horninger, W
    Bartsch, G
    CLINICAL CHEMISTRY, 2003, 49 (06) : A98 - A98
  • [27] Serum PSA recurrence in patients with pT2 prostate cancer.
    McLeod, DG
    Sesterhenn, IS
    Moul, JW
    Mostofi, FK
    JOURNAL OF UROLOGY, 1998, 159 (05): : 61 - 61
  • [28] Real world experience of docetaxel in elderly patients with advanced prostate cancer.
    Fu, Simon Yuen Fai
    Barlow, Paula
    Jacobs, Carmel Maree
    Hanning, Fritha J.
    Fong, Peter C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Time to castration-resistance and docetaxel outcomes in metastatic prostate cancer.
    Aljundi, Lamia
    Miller, Nichole
    Taylor, Andrew
    Hung, Jonathan
    Hwang, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer.
    Roessner, M
    de Wit, R
    Tannock, IF
    Yateman, N
    Yao, SL
    Yver, A
    Eisenberger, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 391S - 391S
12345